DORA Trial: Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
The purpose of this study is to compare any good and bad effects of using radium-223 along with docetaxel chemotherapy treatment versus using docetaxel alone.
- IRB Number: 1808220234 (C16-174)
- Research Study Identifier: TX10172
- Principal Investigator: Roberto Pili, MD
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required